This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary HER2 Therapeutic Antibody Development
The HER2 gene is a significant factor affecting the prognosis of various cancers, influencing cancer cell proliferation and drug resistance through overexpression. Developing veterinary therapeutic antibodies targeting HER2 could bring new solutions to the field of companion animal cancer treatment. BioVenic offers veterinary HER2 therapeutic antibody development services, covering processes including target research, antibody design, production, and functional validation, assisting in the development of high-quality veterinary therapeutic antibodies.
Background of HER2
| Full Name | Erb-b2 receptor tyrosine kinase 2 |
|---|---|
| Aliases | CD340, ERBB2, HER-2/neu, HER2, MLN 19, MLN-19, NEU, NGL, TKR1, VSCN2, c-ERB-2, c-ERB2. |
| Target Profile | HER2 is a member of the epidermal growth factor receptor family and is a transmembrane glycoprotein with tyrosine kinase activity. This protein itself lacks a ligand-binding domain and therefore cannot bind to growth factors. However, it can closely associate with other members of the epidermal growth factor receptor family that bind to ligands, forming heterodimers and enhancing the activation of kinase-mediated downstream signaling pathways. This promotes the invasion and metastasis of cancer cells in the tumor environment. |
MoA of HER2
HER2 typically exists in an inactive monomeric form, with ligand binding to the extracellular domain stabilizing the formation of an active dimer. Dimerization leads to the activation of intracellular tyrosine kinase activity, followed by transphosphorylation of tyrosine residues within the domain, activating signaling pathways such as PI3K-AKT-mTOR and RAS-RAF-MEK-MAPK. These pathways are involved in driving gene transcription that governs cell proliferation, migration, differentiation, and apoptosis downstream. When there is amplification and overexpression of the HER2 gene, it can activate downstream signaling, promoting the invasion and metastasis of cancer cells.
Fig.1 Schematic diagram of HER2 signaling pathways.1
Application in Veterinary Therapeutics
HER2 is overexpressed in various companion animal tumors such as canine urothelial carcinoma, mammary tumors, osteosarcoma, anal sac adenocarcinoma, and transitional cell carcinoma, as well as feline pulmonary carcinoma. Since HER2 lacks a specific ligand, its therapeutic antibodies mainly work by blocking receptor dimerization activation to inhibit HER2 signaling and induce tumor cell cycle arrest, as well as mediating the immune system's cytotoxic effects to suppress tumor cells.
Veterinary HER2 Therapeutic Antibody Development Services
HER2 has the potential to play a key role in the treatment of cancer in companion animals. BioVenic offers services for the development of veterinary therapeutic antibodies targeting the HER2 marker. Our services include the design, production, purification, and functional testing of veterinary therapeutic antibodies to ensure strong specificity and significant effectiveness. We focus not only on the quality and safety of antibody samples but also on the safety and welfare of experimental animals, striving to assist in providing more effective treatment solutions for companion animals.
To learn more about our veterinary HER2 therapeutic antibody development services, please click the link below.
Why Choose Us?
We provide a range of technologies for the development of veterinary therapeutic antibodies, including hybridoma technology, single B-cell technology, and phage display technology.
Our services in antibody engineering encompass procedures like affinity maturation and Fc engineering, aimed at increasing the antibody's affinity and prolonging its half-life.
We specialize in the development of species-specific antibodies, focusing on enhancing the suitability and effectiveness of these antibodies in canine and feline, thereby minimizing the risks related to immunogenicity.
The heightened expression of HER2 in diverse animal tumors can contribute to cancer progression through various mechanisms. BioVenic provides specialized services in the development of veterinary HER2 therapeutic antibodies. Our comprehensive, top-tier service aims to assist you in uncovering the capabilities of veterinary HER2 therapeutic antibodies for treating cancers in companion animals. If you have development needs, please reach out to us now!
Reference
- Ottini, Laura, et al. "HER2-positive male breast cancer: an update." Breast Cancer: targets and therapy (2010): 45-58.